Trading Signals: HTBX Stock Price Prediction and Forecast (Mon. Dec. 28, 2015 - Mon. May. 2, 2022)(Heat Biologics, Inc.)
| HTBX latest price $5.6000 (-5.22%) ($5.6000 - $6.2300) on Mon. May. 20, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.52% (three month average) | RSI | 14 | Latest Price | $5.6000(-5.22%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | HTBX declines -2.3% a day on average for past five trading days. | Weekly Trend | HTBX declines -9.1% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support HTBX advance at 0% a week (0% probability) IGOV(12%) GDX(11%) GDXJ(10%) GLD(10%) MCHI(9%) | Factors Impacting HTBX price | HTBX will decline at least -2.26% in a week (0% probabilities). VCSH(-10%) JETS(-5%) CEMB(-5%) IFRA(-3%) XLV(-2%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.26% (StdDev 4.52%) | Hourly BBV | 0 () | Intraday Trend | -10.1% | | | |
|
1 - 5 Day Possible Target | $-12.81(-328.75%) | Resistance Level | $6.96 | 5 Day Moving Average | $6.01(-6.82%) | 10 Day Moving Average | $6.41(-12.64%) | 20 Day Moving Average | $6.96(-19.54%) | To recent high | -53.8% | To recent low | 0% | Market Cap | $616m | | | | Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC. |